But studies also show that blacks, Hispanics, and Native Americans often have lower projected survival rates than whites and Asians for various diseases. Accordingly, it’s possible that under Obamacare patients from the former three groups would be denied the more expensive (but only marginally more effective) treatments granted patients in the latter two groups.
This wouldn’t be [intentional] disparate treatment; rather, there may be a disparate impact on blacks, Hispanics, and Native Americans based on survivability rates. Since, e.g., blacks (for numerous reasons, including finances, diet/lifestyle, seeking initial treatment much later than whites, etc.) are more likely to die within five years of certain cancer diagnoses than are whites, there may be a greater probability that the more expensive interventions will be withheld from blacks in the aggregate.